Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT00948753

Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation

Safety and Efficacy of Maraviroc, a CCR5-inhibitor in Prophylaxis of Graft-Versus-Host Disease in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation

Sponsor: Abramson Cancer Center at Penn Medicine

Conditions Graft-versus-host Disease Hematopoietic Stem Cell Transplantation

Interventions Maraviroc 150 MG Maraviroc 300 mg Maraviroc 300 mg Phase II

Updated 11 times since 2017 Last updated: Apr 25, 2022 Started: Jun 30, 2009 Primary completion: Apr 30, 2011 Completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Graft-versus-host Disease and Hematopoietic Stem Cell Transplantation and is currently completed. Abramson Cancer Center at Penn Medicine leads this study, which shows 11 recorded versions since 2009 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2023 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2022 — Apr 2023 [monthly]

Completed PHASE1_PHASE2
Apr 2022 — Jun 2022 [monthly]

Completed PHASE1_PHASE2

▶ Show 6 earlier versions

Jan 2021 — Apr 2022 [monthly]

Completed PHASE1_PHASE2
May 2020 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed
Sep 2018 — May 2020 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jun 2018 — Sep 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1_PHASE2

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abramson Cancer Center at Penn Medicine

Data source: Abramson Cancer Center at Penn Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.